NCT01281072
Unknown
Phase 3
Study To Evaluate Long Term Treatment Effect Of Diapep277® In Patients Who Have Completed Study 901 And Study 910** (Extension To 901)
ConditionsGiving a Vaccination in Three Months
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Giving a Vaccination in Three Months
- Sponsor
- Hadassah Medical Organization
- Primary Endpoint
- c peptide reserve
- Last Updated
- 15 years ago
Overview
Brief Summary
Open label study to evaluate long term treatment effect of diapep277.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patient that completed 901 and 910 study.
Exclusion Criteria
- •cpeptide\<0.2
Outcomes
Primary Outcomes
c peptide reserve
Similar Trials
Terminated
Phase 3
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®Type 1 DiabetesNCT01898286Andromeda Biotech Ltd.38
Completed
Phase 3
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)AsthmaNCT02134028Sanofi2,282
Enrolling by Invitation
Phase 3
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT04976322UCB Biopharma SRL760
Recruiting
Phase 3
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlagille SyndromeNCT05035030Albireo, an Ipsen Company70
Completed
Phase 3
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)AsthmaNCT03620747Sanofi393